Biomarker ID | 275 |
PMID | 18446232 |
Year | 2008 |
Biomarker | Methylation Status of (SLC16A12 or DPYS) |
Biomarker Basis | Methylation Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Hypermethylated in Prostate Cancer |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-Beta-alanine metabolism,Pantothenate and CoA biosynthesis,Fluoropyrimidine activity,Drug metabolism: other enzymes,Nucleotide metabolism |
Experiment | prostate cancer Vs normal prostate |
Type of Biomarker | Diagnostic |
Cohort | 20 patients with Tumors were compared to 20 normal patients to study methylation in this study. |
Senstivity | 75% |
Specificity | 95% |
AUC | NA |
Accuracy | 93% |
Level Of Significance | p<0.05 |
Method Used | methylated CpG island amplification (MCA) coupled with representational difference analysis (RDA) |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | SLC16A12, DPYS |